

Supplementary Table 1. HIV patient therapy regimens for non-viremic and viremic patients analyzed in Figure 4.

Patient	Sex	Ethnicity	Status	Treatment	Co-morbidities	HIV Plasma RNA
1	Male	Caucasian	Non-Viremic	Raltegravir, Abacavir/Lamivudine	none	< 0.6
2	Female	Caucasian	Non-Viremic	Ritonavir, Emtricitabine/Tenofovir, Darunavir	none	< 0.6
3	Female	African American	Non-Viremic	Efavirenz/Emtricitabine/Tenofovir	Hepatitis C	< 0.7
4	Male	African American	Non-Viremic	Efavirenz/Emtricitabine/Tenofovir	none	< 0.6
5	Male	African American	Non-Viremic	Atazanavir, Ritonavir, Emtricitabine/Tenofovir	none	3.8
6	Female	African American	Non-Viremic	Atazanavir, Ritonavir, Emtricitabine/Tenofovir	none	0.6
7	Male	African American	Non-Viremic	Efavirenz, Emtricitabine/Tenofovir	Hepatitis C	2.5
8	Male	African American	Non-Viremic	Atazanavir, Ritonavir, Emtricitabine/Tenofovir	Hepatitis C	1.9
9	Male	African American	Non-Viremic	Emtricitabine, Tenofovir, Raltegravir	none	25.7
10	Male	Caucasian	Non-Viremic	Zidovudine, Emtricitabine/Tenofovir, Etravirine, Raltegravir	none	4.3
11	Male	African American	Viremic	Ritonavir, Emtricitabine/Tenofovir, Darunavir	none	866.7
12	Male	African American	Viremic	Treatment naïve	none	17,341
13	Male	Latino	Viremic	Elvitegravir/Cobicistat/Emtricitabine/Tenofovir	none	2,774
14	Male	African American	Viremic	Treatment naïve	none	206,800
15	Male	African American	Viremic	Not on medication	none	564